Harnessing Targeted Protein Degradation

Read how Syngene’s partnership with a leading Biotech company working in the field  of cancer therapy, grew from one small pilot project to over  100 FTEs today. 

Proactive COVID-19 testing

By identifying COVID-19 positive cases early on,  particularly those that are asymtomatic,  we can restrict further transmission of this deadly virus.

Biologics Development and Manufacturing Services

Syngene offers end‑to‑end biologics services across a broad range of modalities and therapeutic areas, including mAbs, recombinant proteins, bispecifics, biosimilars, and antibody–drug conjugates (ADCs).